KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Cash from Investing Activities (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Cash from Investing Activities data on record, last reported at -$198.3 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 65.61% year-over-year to -$198.3 million; the TTM value through Dec 2025 reached -$712.9 million, down 130.82%, while the annual FY2025 figure was -$712.9 million, 130.82% down from the prior year.
  • Cash from Investing Activities reached -$198.3 million in Q4 2025 per EW's latest filing, up from -$427.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $2.7 billion in Q3 2024 and bottomed at -$965.9 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is $15.2 million, with a median of $7.3 million recorded in 2023.
  • The widest YoY moves for Cash from Investing Activities: up 12520.0% in 2024, down 4190.07% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$965.9 million in 2021, then soared by 109.8% to $94.7 million in 2022, then crashed by 85.11% to $14.1 million in 2023, then plummeted by 4190.07% to -$576.7 million in 2024, then surged by 65.61% to -$198.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$198.3 million in Q4 2025, -$427.8 million in Q3 2025, and -$172.1 million in Q2 2025.